ENHERTU AstraZeneca Pty Ltd
Product name
ENHERTU
Sponsor
Accepted date
Sep-2024
Active ingredients
trastuzumab deruxtecan
Proposed indication
Treatment of adult patients with metastatic NSCLC or NSCLC that cannot be removed surgically.
Application type
C (new indication)
Publication date
Sep-2024
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.